KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Other financing activities (2016 - 2025)

HCA Healthcare (HCA) has disclosed Other financing activities for 15 consecutive years, with -$242.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 356.6% to -$242.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$185.0 million, a 33.21% increase, with the full-year FY2025 number at -$185.0 million, up 33.21% from a year prior.
  • Other financing activities was -$242.0 million for Q4 2025 at HCA Healthcare, down from $57.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $254.0 million in Q3 2022 to a low of -$264.0 million in Q3 2024.
  • A 5-year average of -$24.3 million and a median of $2.0 million in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 23800.0% in 2021, then crashed 26500.0% in 2024.
  • HCA Healthcare's Other financing activities stood at $6.0 million in 2021, then surged by 4133.33% to $254.0 million in 2022, then plummeted by 99.61% to $1.0 million in 2023, then crashed by 5400.0% to -$53.0 million in 2024, then crashed by 356.6% to -$242.0 million in 2025.
  • Per Business Quant, the three most recent readings for HCA's Other financing activities are -$242.0 million (Q4 2025), $57.0 million (Q1 2025), and -$53.0 million (Q4 2024).